eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation

Cellular Oncology

Volumn 37, Issue 4, 2014, Pages 253-267

  Spilka, Rita ^a   Ernst, Christina ^b   Bergler, Helmut ^c   Rainer, Johannes ^d   Flechsig, Susanne ^e   Vogetseder, Alexander ^f   Lederer, Eva ^b   Benesch, Martin ^b   Brunner, Andrea ^g   Geley, Stephan ^d   Eger, Andreas ^h   Bachmann, Felix ⁱ   Doppler, Wolfgang ^d   Obrist, Peter ^a   Haybaeck, Johannes ^b  

^a Laboratory of Pathology Dr Obrist and Dr Brunhuber OG   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Experimental Pharmacology and Oncology Berlin Buch GmbH   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^h IMC UNIVERSITY OF APPLIED SCIENCES KREMS   (Austria)

ⁱ BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

eIFs; Eukaryotic translation initiation; Tumour marker; Urinary bladder cancer

Indexed keywords

EUKARYOTIC TRANSLATION INITIATION FACTOR 3A; INITIATION FACTOR 3; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG; EIF3A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL LINE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL MOTILITY; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBOSOME; SURVIVAL RATE; TRANSLATION INITIATION; UPREGULATION; AGED; BLADDER TUMOR; GENETICS; IN VITRO STUDY; METABOLISM; PHYSIOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-3; FEMALE; HUMANS; IN VITRO TECHNIQUES; MALE; PROTEIN BIOSYNTHESIS; URINARY BLADDER NEOPLASMS;

EID: 84906938348     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0181-9     Document Type: Article

References (43)

1. F. Saletta, Y. Suryo Rahmanto, D.R. Richardson, The translational regulator eIF3a: the tricky eIF3 subunit! Biochim. Biophys. Acta 1806, 275-286 (2010)
2. Z. Dong, Z. Liu, P. Cui, R. Pincheira, Y. Yang, J. Liu, J.T. Zhang, Role of eIF3a in regulating cell cycle progression. Exp. Cell Res. 315, 1889-1894 (2009)
3. M. Ploeg, K.K.H. Abden, L.A. Kiemeney, The present and future burden of urinary bladder cancer in the world. World J. Urol. 27, 289-293 (2009)
4. A. Stenzl, N.C. Cowan, M. DeSantis, G. Jakse, M.A. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes, The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 55, 815-825 (2009)
5. M. Retz, J.E. Gschwend, Medikamentöse Tumortherapie in der Uroonkologie, 2nd edn. (Springer, Berlin, 2010)
6. G. Johnen, K. Gawrych, H. Bontrup, B. Pesch, D. Taeger, S. Banek, M. Kluckert, H. Wellhäußer, F. Eberle, M. Nasterlack, G. Leng, A. Stenzl, T. Brüning, Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One 7, e35363 (2012)
7. A. Datta, M.E. Adelson, Y. Mogilevkin, E. Mordechai, A.A. Sidi, J.P. Trama, Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer 11, 234 (2011)
8. V. Cebrian, M. Fierro, E. Orenes-Piñero, L. Grau, P. Moya, T. Ecke, M. Alvarez, M. Gil, F. Algaba, J. Bellmunt, C. Cordon-Cardo, J. Catto, A. López-Beltrán, M. Sánchez-Carbayo, KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. Am. J. Pathol. 179, 540-546 (2011)
9. L.G. Koss, E.M. Tiamson, M.A. Robbins, Mapping cancerous and precancerous bladder changes. JAMA 227, 281-286 (1974)
10. P.E. Spiess, B. Czerniak, Dual-track pathway of bladder carcinogenesis: practical implications. Arch. Pathol. Lab. Med. 130, 844-852 (2006)
11. T.V. Pestova, J.R. Lorsch, C.U.T. Hellen, The Mechanism of Translation Initiation in Eukaryotes, in Translational Control in Biology and Medicine, ed. by M.B. Mathews, N. Sonenberg, J.W.B. Hershey (Cold Spring Harbor Laboratory Press, New York, 2007), pp. 87-128
12. A. Unbehaun, S.I. Borukhov, C.U.T. Hellen, T.V. Pestova, Release of initiation factors from 48S complexes during ribosomal subunit joining and the link between establishment of codon-anticodon base-pairing and hydrolysis of eIF2-bound GTP. Genes Dev. 18, 3078-3093 (2004)
13. T. Kouba, I. Danyi, S. Gunisova, V. Munzarova, V. Vlckova, L. Cuchalova, A. Neueder, P. Milkereit, L.S. Valasek, Small ribosomal protein RPS0 stimulates translation initiation by mediating 40S-binding of eIF3 via its direct contact with the eIF3a/TIF32 subunit. PLoS One 7, e40464 (2012)
14. R.Y. Liu, Z. Dong, J. Liu, J.Y. Yin, L. Zhou, X. Wu, Y. Yang, W. Mo, W. Huang, S.K. Khoo, J. Chen, D. Petillo, B.T. Teh, C.N. Qian, J.T. Zhang, Role of eIF3a in regulating cisplatin sensitivity and nucleotide excision repair of nasopharyngeal carcinomas. Oncogene 30, 4814-4823 (2012)
15. J.Y. Yin, J. Shen, Z.Z. Dong, Q. Huang, M.Z. Zhong, D.Y. Feng, H.H. Zhou, J.T. Zhang, Z.Q. Liu, Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin. Cancer Res. 17, 4600-4609 (2011)
16. R. Spilka, K. Laimer, F. Bachmann, G. Spizzo, A. Vogetseder, M. Wieser, H. Müller, J. Haybaeck, P. Obrist, Overexpression of eIF3a in squamous cell carcinoma of the oral cavity and its putative relation to chemotherapy response. J. Oncol. 901956 (2012)
17. R. Gentleman, V. Carey, D. Bates, B. Bolstad, Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004)
18. Z. Wu, R.A. Irizarry, R. Gentleman, F. Martinez Murillo, F. Spencer, A model based background adjustment for oligonucleotide expression arrays. Johns Hopkins University, Dept. of Biostatistics Working Papers. Working Paper 1 (2004)
19. G.K. Smyth, Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, e29 (2004)
20. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R Stat. Soc. Ser. B 57, 289-300 (1995)
21. S. Falcon, R. Gentleman, Using GOstats to test gene lists for GO term association. Bioinformatics 23, 257-258 (2007)
22. G. Spizzo, D. Fong, M. Wurm, C. Ensinger, P. Obrist, C. Hofer, G. Mazzoleni, G. Gastl, P. Went, EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 64, 415-420 (2011)
23. J. Bubeník, M. Baresová, V. Viklický, J. Jakoubková, H. Sainerová, J. Donner, Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int. J. Cancer 11, 765-773 (1973)
24. J. Fogh, Cultivation, characterization and identification of human tumor cells with emphasis on kidney, testis and bladder tumors. Natl. Cancer Inst. Monogr. 49, 5-9 (1978)
25. C.J. Marshall, L.M. Franks, A.W. Carbonell, Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J. Nat. Cancer Inst. 58, 1743-1751 (1977)
26. V. Croons, W. Martinet, A.G. Herman, G.R. De Meyer, Differential effect of the protein synthesis inhibitors puromycin and cycloheximide on vascular smooth muscle cell viability. J. Pharmacol. Exp. Ther. 325, 824-832 (2008)
27. S. Pestka, Inhibitors of ribosome functions. Annu. Rev. Microbiol. 25, 487-562 (1971)
28. X. Wang, C.G. Proud, The mTOR pathway in the control of protein synthesis. Physiology 21, 362-369 (2006)
29. K. Inoki, H. Ouyang, Y. Li, K.L. Guan, Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev. 69, 79-100 (2005)
30. S. Khoshnevis, S. Gunisová, V. Vlcková, T. Kouba, P. Neumann, P. Beznosková, R. Ficner, L.S. Valásek, Structural integrity of the PCI domain of eIF3a/TIF32 is required for mRNA recruitment to the 43S pre-initiation complexes. Nucleic Acids Res. 42, 4123-4139 (2014)
31. A.G. Hinnebusch, eIF3: a versatile scaffold for translation initiation complexes. Trends Biochem. Sci. 31, 553-562 (2006)
32. F. Bachman, R. Baenziger, M.M. Burger, Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res. 57, 988-994 (1997)
33. A. Dellas, J. Torhorst, F. Bachmann, R. Baenziger, E. Schultheiss, M.M. Burger, Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer 83, 1376-1383 (1998)
34. G. Chen, M.M. Burger, P150 expression and its prognostic value in squamous cell carcinoma of the esophagus. Int. J. Cancer 84, 95-100 (1999)
35. R. Pincheira, Q. Chen, J.T. Zhang, Identification of a 170-kDa protein over-expressed in lung cancers. Br. J. Cancer 84, 1520-1527 (2001)
36. G. Chen, M.M. Burger, P150 Overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int. J. Cancer 112, 393-398 (2004)
37. J. Haybaeck, T. O'Connor, R. Spilka, G. Spizzo, C. Ensinger, G. Mikuz, T. Brunhuber, A. Vogetseder, I. Theurl, W. Salvenmoser, H. Draxl, R. Baenziger, F. Bachmann, G. Schaefer, M.M. Burger, P. Obrist, Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res. 30, 1047-1056 (2010)
38. K.C. Halling, W. King, I.A. Sokolova, R.J. Karnes, R.G. Meyer, E.L. Powell, T.J. Sebo, J.C. Cheville, A.C. Clayton, K.L. Krajnik, T.A. Ebert, R.E. Nelson, H.M. Burkhardt, S. Ramakumar, C.S. Stewart, V.S. Pankratz, M.M. Lieber, M.L. Blute, H. Zincke, S.A. Seelig, R.B. Jenkins, D.J. O'Kane, A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J. Urol. 167, 2001-2006 (2002)
39. H. Jamshidian, K. Kor, M. Djalali, Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol. J. 5, 243-247 (2008)
40. L.P. Huang, D. Savoly, A.A. Sidi, M.E. Adelson, E. Mordechai, J.P. Trama, CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med. 1, 76-81 (2012)
41. Y.C. Lu, C.N. Chen, B. Wang, W.M. Hsu, S.T. Chen, K.J. Chang, C.C. Chang, H. Lee, Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am. J. Pathol. 179, 1425-1433 (2011)
42. M. Unoki, J.D. Kelly, D.E. Neal, B.A. Ponder, Y. Nakamura, R. Hamamoto, UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br. J. Cancer 101, 98-105 (2009)
43. D. Silvera, S.C. Formenti, R.J. Schneider, Translational control in cancer. Nat. Rev. Cancer 10, 254-266 (2010)